MET Amplification NSCLC Test: Comprehensive Genetic Analysis for Lung Cancer
Understanding MET Amplification in Non-Small Cell Lung Cancer
The MET Amplification NSCLC Test represents a breakthrough in precision oncology, specifically designed to detect MET gene amplification in patients with non-small cell lung cancer. This sophisticated genetic analysis plays a crucial role in identifying patients who may benefit from targeted therapies directed against the MET pathway. As lung cancer treatment evolves toward personalized medicine, understanding specific genetic alterations like MET amplification becomes essential for optimizing patient outcomes and developing effective treatment strategies.
What Does the MET Amplification Test Measure?
This advanced diagnostic test specifically detects and quantifies MET gene amplification using Fluorescence In Situ Hybridization (FISH) technology. The test analyzes:
- MET gene copy number variations in tumor cells
- Amplification levels that may indicate sensitivity to MET inhibitors
- Genetic alterations that drive cancer progression and treatment resistance
- Paraffin-embedded tumor tissue blocks for comprehensive analysis
Technical Methodology
Our FISH-based testing methodology provides highly accurate detection of MET amplification by using fluorescent probes that bind specifically to the MET gene region. This approach allows for precise quantification of gene copy numbers and identification of amplification patterns that correlate with treatment response.
Who Should Consider MET Amplification Testing?
This test is particularly important for patients experiencing:
- Advanced non-small cell lung cancer with progression on standard therapies
- Resistance to EGFR tyrosine kinase inhibitors
- Need for alternative treatment options after initial therapy failure
- Suspected MET-driven tumor growth patterns
- Planning for targeted therapy regimens
Clinical Indications
Patients diagnosed with NSCLC adenocarcinoma, squamous cell carcinoma, or other non-small cell lung cancer subtypes may benefit from MET amplification testing, especially when conventional treatments show limited effectiveness or when exploring targeted therapy options becomes necessary.
Benefits of MET Amplification Testing
Undergoing MET amplification testing provides numerous advantages for lung cancer patients:
- Personalized Treatment Planning: Identifies patients who may respond to MET-targeted therapies
- Improved Outcomes: Enables selection of more effective treatment strategies
- Reduced Treatment Toxicity: Helps avoid ineffective therapies and their associated side effects
- Informed Decision Making: Provides crucial information for oncologists to develop optimized treatment plans
- Comprehensive Genetic Profiling: Complements other biomarker testing for complete molecular characterization
Understanding Your Test Results
Your MET amplification test results will provide valuable insights into your cancer’s genetic profile:
Interpretation Guidelines
- Positive for MET Amplification: Indicates increased MET gene copies, suggesting potential benefit from MET-targeted therapies
- Negative for MET Amplification: Normal MET gene copy numbers, indicating alternative treatment approaches may be more appropriate
- Borderline Results: May require additional testing or clinical correlation
It’s essential to discuss your results with your oncologist, who will interpret them in the context of your overall clinical picture and treatment history. Our genetic counselors are available to help you understand your results and their implications for your treatment journey.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| MET Amplification NSCLC Test – Discount Price | $226 |
| MET Amplification NSCLC Test – Regular Price | $300 |
Test Details
- Turnaround Time: 7-8 days
- Sample Type: Tumor tissue (paraffin-embedded tissue blocks)
- Testing Method: FISH (Fluorescence In Situ Hybridization)
- Prescription Requirements: Doctor’s prescription required (not applicable for surgery, pregnancy cases, or international travel planning)
Nationwide Testing Availability
We have testing facilities conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our nationwide network ensures accessible, high-quality genetic testing for lung cancer patients throughout the country.
Take Action for Your Health Today
Don’t leave your treatment decisions to chance. Understanding your cancer’s genetic profile through MET amplification testing can open doors to more effective, personalized treatment options. Our team of genetic specialists and oncology experts are ready to support you through every step of the testing process.
Ready to schedule your MET Amplification NSCLC Test? Contact us today at +1(267) 388-9828 to speak with our genetic counseling team or to book your test appointment. Take the first step toward personalized lung cancer treatment and improved outcomes.
Early detection of MET amplification can significantly impact your treatment journey. Call now to learn more about how this advanced genetic testing can benefit your specific situation and help your healthcare team develop the most effective treatment strategy for your non-small cell lung cancer.
